Results For "Q2-2026-Biosimilar-Market-Report"

1 News Found

Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report

Biopharma | April 28, 2026

Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report

Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation

Latest Stories

Apollo launches its 76th hospital, boosts tech-led healthcare in India

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Concept Medical unveils promising 3-year data for sirolimus balloon therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.

Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor

Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor

Ganesh Bade Director Bioprocessing–IMEA, Avantor

We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET

We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET

Saurav Kasera Founder, CLIRNET

Packaging